Inclusion Criteria:
- Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria
- Active axial disease at Screening and Baseline defined by a Bath Ankylosing
- Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4
- Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each
- Participant has never received a biologic therapy eg, tumor necrosis factor (TNF)
antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or
have taken more than one biologic therapy (biologic-failure substudy) for the
treatment of AS
Exclusion Criteria:
- Radiographic evidence of total ankylosis of the spine
- Clinically significant back pain caused by diseases other than AS
- Concurrent treatment or treatment within the 6 months prior to Baseline with cell
depleting biologic agents
- Participation in any study of an investigational drug, including those for COVID-19
- History of malignancy
- Oral corticosteroids (prednisone or equivalent) > 10 mg/day systemically for ≥ 2 weeks
prior to Baseline Visit
